1 De Beer L,Stokroos R,Kingma H,et al.Intratympanic genta-micin therapy for intractable Meniere’s disease[J].Acta Oto-laryngol,2007,127:605.

2 Derebery MJ,Fisher LM,Berliner K.Outcomes of endolym-phatic shunt surgery for Ménière's disease:comparison with in-tratympanic gentamicin on vertigo control and hearing loss[J].Otol Neurotol,2010,31:649.

3 Zhai F,Liu JP,Dai CF.Evidence-based modification of intra-tympanic gentamicin injections in patients with intractable ver-tigo[J].Otol Neurotol,2010,31:642.

4杨军,吴皓.鼓室内给药治疗内耳疾病的基础与临床[J].中华耳鼻咽喉科杂志,2004,39:770.

5 Büki B,Platz M,Haslwanter T.Results of electrocochleogra-phy in Ménière's disease after successful vertigo control by sin-gle intratympanic gentamicin injection[J].Audiol Neurootol.2011,16:49.

6 Parnes LS,Sun AH,Freeman DJ.Corticosteroid pharmacoki-netics in the inner ear fluids:an animal study followed by clini-cal application[J].Laryngoscope,1999,109:1.

7高文元.氨基糖苷类抗生素耳毒性及其预防的研究进展[J].中国眼耳鼻喉科杂志,2008,8:273.

8刘建平,戴春富,王正敏.庆大霉素鼓室内注射后在内耳细胞中的分布[J].中华耳鼻咽喉头颈外科杂志,2006,41:851.

9闫艾慧,姜学钧.郝帅.银杏叶提取物对庆大霉素耳毒性保护作用的实验研究[J].中国医科大学学报,2007,36:212.

10 Habtemichael N,Heinrich UR,Knauer SK.Expression a-nalysis suggests a potential cytoprotective role of Birc5 in theinner ear[J].Mol Cell Neurosci,2010,45:297.

11 Salt AN,Ma Y.Quantification of solute entry into cochlearperilymph through the round window membrane[J].HearRes,200l,154:88.

12 Salt AN.Simulation of methods for drug delivery to the co-chlear fluids[J].Adv otorhinoIaryngol,2002,59:140.

13 Chen Z,Duan M,Lee H,et al.Pharmacokinetics of caroverinein the inner ear and its effects on cochlear function after sys-temic and local administrations in Guinea pigs[J].AudiolNeurootol,2003,8:49.

14 Bachmann G,Su J,Zumegen C,et al.Permeability of theround window membrane for prednisolone-21-hydrogensuccinate.Prednisolone content of the perilymph after localadministration vs systemic injection[J].HNO,2001,49:538.

15 Hibi T,Suzuki T,Nakashima T.Perilymphatic concentrationof gentamicin administered intratympanically in guinea pigs[J].Acta Otolaryngol,2001,121:336..

16 Plontke SK,Salt AN.Simulation of application strategies forlocal drug delivery to the inner ear[J].ORI,J Otorhinolaryn-gol Relat Spec,2006,68:386.

17 Mynatt R,Hale SA,Gill RM,et al.Demonstration of a longi-tudinal concentration gradient along scala tympani by sequen-tial sampling of perilymph from the cochlear apex[J].J AssocRes Otolaryngol,2006,7:182.

18 Plontke SK,Wood AW,Salt AN.Analysis of gentamicin ki-netics in fluids of the inner ear with round window adminis-tration[J].Otol Neurotol,2002,23:967.

19 Wagner N,Caye-Thomasen P,Laurell G,et a1.Cochlearhair cell loss in singledose versus continuous round windowadministration of gentamicin[J].Acta Otolaryngol,2005,125:340.

20 Plontke SK,Mynatt R,Gill RM,et a1.Concentration gradientalong the scala tympani after local application of gentamicinto the round window membrane[J].Larynscope,2007,117:1 191.

21 Chandrasekhar SS,Rubinstein RY,Kwartler JA,et al.Dexa-methasone pharmacokinetics in the inner ear:comparison ofroute of administration and use of facilitating agents[J].Oto-laryngol Head Neck Surg,2000,122:521.

22 Selivanova O,Maurer J,Ecke U,et al.The effects of streptol-ysin-O and sodium hyaluronate on the permeability of theround window membrane in guinea pigs an electrophysiologicstudy[J].Laryngorhinootologie,2003,82:235.

23 Yoshioka M,Naganawa S,Sone M,et al.Individual differ-ences in the permeability of the round window:evaluating themovement of intratympanic gadolinium into the inner ear[J].Otol Neurotol,2009,30:645.

24 Crane BT,Minor LB,Della Santina CC.Middle ear explora-tion in patients with Ménière's disease who have failed outpa-tient intratympanic gentamicin therapy[J].Otol Neurotol,2009,30:619.

25 Salt AN,Kellner C,Hale S.Contamination of perilymph sampiedfrom the basal cochlear turn with cerebrospinal fluid[J].HearRes,2003,182:24.

26 Plontke SK,Salt AN.Simulation of application strategies forlocal drug delivery to the inner ear[J].ORI,J Otorhinolaryn-gol Relat Spec,2006,68:386.

27 Hoffer ME,Balough BJ,Gottshall KR,et al.Sustained-re-lease devices in inner ear medical thempy[J].Otolaryngol ClinN Am,2004,37:1 053.

28 Hsieh LC,Lin HC,Tsai HT.High-dose intratympanic genta-micin instillations for treatment of Meniere's disease:long-termresults[J].Acta Otolaryngol,2009,129:1 420.

29 Salt AN,Gill RM,Plontke SK.Dependence of hearing chan-ges on the dose of intratympanically applied gentamicin:ameta-analysis using mathematical simulations of clinicaldrug delivery protocols[J].Laryngoscope.2008,118:1 793.

30 Martin E,Pere Z.Hearing loss after intratympanic gentamicintherapy for unilateral Meniere’s disease[J].Otol Neurotol,2003,24:800.

31 Colletti V,Carner M,Colletti L.Auditory results after ves-tibular nerve section and intratympanic gentamicin forMénière's disease[J].Otol Neurotol,2007,28:145.

32 Kyrodimos E,Aidonis I,Sismanis A.Hearing results follow-ing intratympanic gentamicin perfusion for Ménière's disease[J].J Laryngol Otol,2009,123:379.

33 Gunesh PR,Sobani D,Marcus DA,et al.long-term effects ofthe Mentlt device in Meniere’s disease:the Western Austril-ian experience[J].J Laryngol Otol,2005,119:391.

34 Ozluoglu LN,Akkuzu G,Ozgirgin N,et al.Reliability of thevestibular evoked myogenic potential test in assessing intra-tympanic gentamicin therapy in Meniere's disease[J].ActaOtolaryngol,2008,128:422.

35 Salvinelli F,Trivellli M,Greco F,et al.Meniere's disease:is ita bilater disease[J]Eur Rev Med Pharmacol Sci,1999,3:129.

36 Conlon BJ,Gibson WP.Meniere's disease:the incidence of hy-drops in the contralateral asymptomatic ear[J].Laryngo-scope,1999,109:1 800.